JP2024506016A5 - - Google Patents

Info

Publication number
JP2024506016A5
JP2024506016A5 JP2023547398A JP2023547398A JP2024506016A5 JP 2024506016 A5 JP2024506016 A5 JP 2024506016A5 JP 2023547398 A JP2023547398 A JP 2023547398A JP 2023547398 A JP2023547398 A JP 2023547398A JP 2024506016 A5 JP2024506016 A5 JP 2024506016A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023547398A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506016A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/015496 external-priority patent/WO2022170193A2/en
Publication of JP2024506016A publication Critical patent/JP2024506016A/ja
Publication of JP2024506016A5 publication Critical patent/JP2024506016A5/ja
Pending legal-status Critical Current

Links

JP2023547398A 2021-02-08 2022-02-07 免疫療法のためのt細胞免疫グロブリン及びムチンドメイン3(tim3)組成物及び方法 Pending JP2024506016A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163147221P 2021-02-08 2021-02-08
US63/147,221 2021-02-08
PCT/US2022/015496 WO2022170193A2 (en) 2021-02-08 2022-02-07 T-cell immunoglobulin and mucin domain 3 (tim3) compositions and methods for immunotherapy

Publications (2)

Publication Number Publication Date
JP2024506016A JP2024506016A (ja) 2024-02-08
JP2024506016A5 true JP2024506016A5 (cg-RX-API-DMAC7.html) 2025-02-21

Family

ID=80819858

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547398A Pending JP2024506016A (ja) 2021-02-08 2022-02-07 免疫療法のためのt細胞免疫グロブリン及びムチンドメイン3(tim3)組成物及び方法

Country Status (5)

Country Link
US (1) US20230374456A1 (cg-RX-API-DMAC7.html)
EP (1) EP4288089A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024506016A (cg-RX-API-DMAC7.html)
CN (1) CN117042794A (cg-RX-API-DMAC7.html)
WO (1) WO2022170193A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3551757A1 (en) * 2016-12-08 2019-10-16 Intellia Therapeutics, Inc. Modified guide rnas
JP2024534114A (ja) * 2021-08-24 2024-09-18 インテリア セラピューティクス,インコーポレイテッド 細胞療法用のプログラム細胞死タンパク質1(pd1)組成物及び方法
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
TW202617987A (zh) * 2024-06-26 2026-05-01 美商英特利亞醫療公司 用於基因體編輯之經修飾之嚮導rna

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
ATE515510T1 (de) 1991-12-24 2011-07-15 Isis Pharmaceuticals Inc Durch dna-abschnitte unterbrochene modifizierte oligonukleotide
EP0760008A1 (en) 1994-05-19 1997-03-05 Dako A/S Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis
PT2931898E (pt) 2012-12-12 2016-06-16 Harvard College Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
IL308158A (en) 2012-12-17 2023-12-01 Harvard College Rna-guided human genome engineering
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
WO2015200555A2 (en) 2014-06-25 2015-12-30 Caribou Biosciences, Inc. Rna modification to engineer cas9 activity
CN106794141B (zh) 2014-07-16 2021-05-28 诺华股份有限公司 将核酸包封在脂质纳米粒主体中的方法
AU2016226077B2 (en) 2015-03-03 2021-12-23 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases with altered PAM specificity
EP3294342A4 (en) * 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
AU2016262093B2 (en) * 2015-05-13 2022-08-18 Seattle Children' S Hospital (Dba Seattle Children 's Research Institute) Enhancing endonuclease based gene editing in primary cells
WO2017093969A1 (en) 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
WO2017136794A1 (en) 2016-02-03 2017-08-10 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
ES3030658T3 (en) 2016-03-30 2025-07-01 Intellia Therapeutics Inc Lipid nanoparticle formulations for crispr/cas components
EP3551757A1 (en) 2016-12-08 2019-10-16 Intellia Therapeutics, Inc. Modified guide rnas
CN109790518A (zh) * 2017-05-08 2019-05-21 中国科学院动物研究所 经修饰的t细胞、其制备方法及用途
JP7170666B2 (ja) 2017-05-08 2022-11-14 プレシジョン バイオサイエンシズ,インク. 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法
US11738047B2 (en) * 2017-12-12 2023-08-29 The Trustees Of The University Of Pennsylvania Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof
WO2019147805A2 (en) 2018-01-26 2019-08-01 The Board Of Trustees Of The Leland Stanford Junior University Regulatory t cells targeted with chimeric antigen receptors
US11447769B2 (en) 2018-03-27 2022-09-20 The Trustees Of The University Of Pennsylvania Modified immune cells having enhanced function and methods for screening for same
JP7832761B2 (ja) 2018-06-08 2026-03-18 インテリア セラピューティクス,インコーポレイテッド 遺伝子編集のための修飾されたガイドrna
EP3581200A1 (en) 2018-06-13 2019-12-18 GEMoaB Monoclonals GmbH Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
CA3116132A1 (en) 2018-10-16 2020-04-23 Intellia Therapeutics, Inc. Compositions and methods for immunotherapy
WO2020092057A1 (en) 2018-10-30 2020-05-07 Yale University Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
KR20230017783A (ko) 2020-04-28 2023-02-06 인텔리아 테라퓨틱스, 인크. 시험관내 세포 전달 방법

Similar Documents

Publication Publication Date Title
JP2025511899A5 (cg-RX-API-DMAC7.html)
JP2023171775A5 (cg-RX-API-DMAC7.html)
JP2022184985A5 (cg-RX-API-DMAC7.html)
JP2023166402A5 (cg-RX-API-DMAC7.html)
JP2023103258A5 (cg-RX-API-DMAC7.html)
JP2024116190A5 (cg-RX-API-DMAC7.html)
JP2021184963A5 (cg-RX-API-DMAC7.html)
JP2023145572A5 (cg-RX-API-DMAC7.html)
JP2023116721A5 (cg-RX-API-DMAC7.html)
JP2025160243A5 (cg-RX-API-DMAC7.html)
JP2022541332A5 (cg-RX-API-DMAC7.html)
JP2025176106A5 (cg-RX-API-DMAC7.html)
JP2022543046A5 (cg-RX-API-DMAC7.html)
JP2023514727A5 (cg-RX-API-DMAC7.html)
JP2023181322A5 (cg-RX-API-DMAC7.html)
JP2023100857A5 (cg-RX-API-DMAC7.html)
JP2023552816A5 (cg-RX-API-DMAC7.html)
JP2022116141A5 (cg-RX-API-DMAC7.html)
JP2024045126A5 (cg-RX-API-DMAC7.html)
JP2025098156A5 (cg-RX-API-DMAC7.html)
JP2023512729A5 (cg-RX-API-DMAC7.html)
JP2023093656A5 (cg-RX-API-DMAC7.html)
JP2023078173A5 (cg-RX-API-DMAC7.html)
JP2024149687A5 (cg-RX-API-DMAC7.html)
JP2024099585A5 (cg-RX-API-DMAC7.html)